In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.
The MIC of the novel antituberculosis (anti-TB) drug AZD5847 was determined against 146 clinical isolates from diverse geographical regions, including eastern Europe, North America, Africa, and Asia, using the automated Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system. These isolates originated from specimen sources such as sputum, bronchial alveolar lavage fluid, pleural fluid, abscess material, lung biopsies, and feces. The overall MIC90 was 1.0 mg/liter (range, 0.125 to 4 mg/liter). The MICs of AZD5847 for isolates of Mycobacterium tuberculosis were similar among drug-sensitive strains, multidrug-resistant (MDR) strains, and extensively drug resistant (XDR) strains. The good in vitro activity of AZD5847 against M. tuberculosis and the lack of cross-resistance make this agent a promising anti-TB drug candidate.
The Public Health Agency of Sweden, Department of Microbiology, Unit of Highly Pathogenic Bacteria, Solna, Sweden jim.werngren@folkhalsomyndigheten.se dr_crodrigues@hindujahospital.com.
Jim
J
Werngren
The Public Health Agency of Sweden, Department of Microbiology, Unit of Highly Pathogenic Bacteria, Solna, Sweden.
Maria
M
Wijkander
Karolinska University Hospital, Laboratory Medicine, Department of Pathology, Huddinge, Sweden.
Nasrin
N
Perskvist
Infection Innovative Medicines Unit, AstraZeneca R&D, Bangalore, India.
V
V
Balasubramanian
Infection Innovative Medicines Unit, AstraZeneca R&D, Bangalore, India.
Vasan K
VK
Sambandamurthy
P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India jim.werngren@folkhalsomyndigheten.se dr_crodrigues@hindujahospital.com.
Camilla
C
Rodrigues
The Public Health Agency of Sweden, Department of Microbiology, Unit of Highly Pathogenic Bacteria, Solna, Sweden.
Sven
S
Hoffner
D000995:Antitubercular Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D023303:Oxazolidinones / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D023303:Oxazolidinones; C453362:posizolid